Investigation of treatment expectancy in patients with atopic dermatitis undergoing a modern system therapy

Investigation of treatment expectancy in patients with atopic dermatitis undergoing a modern system therapy - ADvance

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032191

Enrollment

100

Registered

2023-07-03

Start date

2023-08-16

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L20

Interventions

Group 1: Patients with atopic dermatitis who are initiated on systemic therapy will complete various questionnaires prior to initiation and after 4 and 16 weeks on therapy. Furthermore, blood samples

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients with atopic dermatitis and indication for initiation of systemic therapy. - Women of childbearing potential with contraception (according to the Standard of Care)

Exclusion criteria

Exclusion criteria: - Pregnancy and breast-feeding; lack of willingness to use effective contraception. - Insufficient ability to communicate in the German language or lack of understanding of the German language; dementia or (functional) illiteracy. - Lacking or absent capacity of the patient to give consent - Presence of contraindications to systemic therapy with an IL-4 and IL-13 blocker or a JAK inhibitor.

Design outcomes

Primary

Measure	Time frame
- Subjective pror experiences, expectations as well as perception of warmth and competence at the beginning and during the course of therapy - Correlation of recorded psychological factors and skin symptoms before and during therapy - Correlation of recorded psychological factors and perceived treatment success - Comparison of proinflammatory cytokines in blood serum (especially IL-4, IL-5, IL-13, IL-31) and serum cortisol before the start of therapy and 16 weeks after therapy initiation - Development of symptom burden and treatment satisfaction, measured using Ecological Momentary Assessment	—

Measure

Time frame

- Subjective pror experiences, expectations as well as perception of warmth and competence at the beginning and during the course of therapy - Correlation of recorded psychological factors and skin symptoms before and during therapy - Correlation of recorded psychological factors and perceived treatment success - Comparison of proinflammatory cytokines in blood serum (especially IL-4, IL-5, IL-13, IL-31) and serum cortisol before the start of therapy and 16 weeks after therapy initiation - Development of symptom burden and treatment satisfaction, measured using Ecological Momentary Assessment

—

Secondary

Measure	Time frame
- Association of recorded psychological factors and therapy success with the level of proinflammatory cytokines and serum cortisol. - Associations of psychological factors prior experience, expectancy, and perceptions of warmth and competence with each other - Correlations of proinflammatory cytokine activity with plasma cortisol activity	—

Countries

Germany

Contacts

Public ContactWiebke Sondermann

Universitätsklinikum Essen (AöR), Klinik für Dermatologie, Venerologie und Allergologie

wiebke.sondermann@uk-essen.de0049 201 723 3647

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026